# NextCure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nextcure

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.nextcure.com
- Total disclosed funding: $160M
- Latest round: Series B (Nov 13, 2018)
- Investors on record: 15

## About

NextCure, Inc. is a biopharmaceutical company focused on developing immunomedicines to treat various cancers and immune-related diseases by leveraging the body's immune system.Founded in 2015 and headquartered in the United States, NextCure, Inc. specializes in immunomedicine development. In May 2019, the company successfully raised USD 75 mn through an IPO, selling 5 million shares at USD 15 per share on the Nasdaq. The company has completed a total of 3 deals to date, with no noted changes in business strategy or structure.NextCure, Inc. specializes in developing innovative immunomedicines aimed at addressing unmet medical needs in oncology and other immune-related disorders. Their primary offerings include proprietary antibody-based therapeutics designed to target key pathways involved in tumor progression and immune evasion, advancing through clinical trials in North America and Europe. Their clientele encompasses healthcare providers, research institutions, and pharmaceutical companies engaged in immunotherapy.For the most recent year, 2021, NextCure reported zero revenue, with an EBITDA of USD -64.71 mn reported for 2023. The company generates revenue through B2B partnerships and collaborations, focusing on milestone payments and potential royalties from its immunomedicine products, alongside licensing agreements for its proprietary technologies.NextCure, Inc. aims to leverage recent funding from its IPO in May 2019 to enhance its product development pipeline and expand its clinical trials. The company is focused on launching new products that specifically target critical therapeutic areas in immunology and oncology, with strategic expansion plans into additional markets in North America and Europe. The funds raised will support these initiatives and facilitate entry into new geographic regions.

## Funding rounds

- Series B, Nov 13, 2018, $93M — OrbiMed Advisors, Sofinnova Investments, Canaan Partners, Alexandria Venture Investments, Bay City Capital, Lilly Asia Ventures, Pfizer Inc., Surveyor Capital, ArrowMark Partners, Ping An Trust, Hillhouse Investment, Eli Lilly & Company, Taiho Ventures, Timefolio Capital, Quan Capital
- Series A, Jan 6, 2016, $67M — OrbiMed Advisors, Sofinnova Investments, Canaan Partners, Alexandria Venture Investments, Lilly Asia Ventures, Pfizer Inc.

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Pfizer Inc. — Series A, Series B
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B
- Surveyor Capital — Series B
- ArrowMark Partners — Series B
- Ping An Trust — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- Eli Lilly & Company — Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series B
- Timefolio Capital — Series B
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series B